光子计数探测器CT用于冠状动脉疾病诊断的成本效益:芬兰医疗视角
本研究基于已发表的冠状动脉疾病报告与数据系统重分类数据,构建决策树并采用蒙特卡洛模拟(10,000例虚拟患者,10年扫描仪寿命),比较光子计数探测器CT与能量积分探测器CT在芬兰医疗情境下的成本效益;结果显示光子计数探测器CT显著降低下游诊断检查费用,在高通量中心具有成本效益。
要点
- 光子计数探测器CT较能量积分探测器CT降低下游诊断检查费用,情景1降低33.8%,情景2降低26.9%(均p<0.001)。
- 光子计数探测器CT在情景1和情景2中分别于7,880例和4,950例患者后达到成本效益阈值。
- 作者认为光子计数探测器CT在高通量中心是能量积分探测器CT的成本效益替代方案。
核心结论
- 光子计数探测器CT在高通量中心是能量积分探测器CT的成本效益替代方案,通过提高诊断准确性减少不必要的下游检查;这些发现支持其在芬兰医疗系统中采用。
研究设计与样本
- 基于已发表的冠状动脉疾病报告与数据系统重分类数据,构建两个决策树(情景1基于既往发表研究的诊断路径,情景2反映本地临床实践),纳入本地成本数据,采用自举蒙特卡洛模拟10,000例虚拟患者、10年扫描仪寿命,并设定光子计数探测器CT较能量积分探测器CT溢价1,500,000欧元以确定盈亏平衡点。
临床应用与阅片要点
- 作者认为光子计数探测器CT在高通量中心是能量积分探测器CT的成本效益替代方案,支持其在芬兰医疗系统中采用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The purpose of this study was to evaluate the cost-effectiveness of photon-counting detector computed tomography (PCD-CT) compared to energy-integrating detector CT (EID-CT) for coronary artery disease (CAD) diagnostics in the Finnish healthcare context.
METHODS: Two decision trees, incorporating local cost data and diagnostic pathways, were developed based on previously published Coronary Artery Disease - Reporting and Data System reclassification data for PCD-CT and EID-CT. A bootstrapping Monte Carlo simulation was used to model 10,000 virtual patients across a 10-year scanner lifespan. Two diagnostic scenarios were considered: one based on the diagnostic pathway of a previously published study (scenario 1) and another reflecting local clinical practice (scenario 2). Downstream testing costs and total diagnostic costs of both PCD-CT and EID-CT branches were assessed. The break-even point for PCD-CT investment was determined by including an assumed €1,500,000 price premium over EID-CT.
RESULTS: PCD-CT significantly reduced downstream diagnostic testing compared to EID-CT. In scenario 1, mean downstream costs per patient were €377.1 ± 11.5 for PCD-CT and €569.7 ± 11.7 for EID-CT, (33.8 % reduction, p < 0.001). In scenario 2, downstream costs were €831.7 ± 19.7 for PCD-CT and €1138.2 ± 18.3 for EID-CT (26.9 % reduction, p < 0.001). Total diagnostic costs, including CCTA, were also lower with PCD-CT. The cost-benefit threshold was reached after 7,880 and 4,950 patients for scenarios 1 and 2 respectively.
CONCLUSIONS: PCD-CT would be a cost-effective alternative to EID-CT in high-volume centers, reducing unnecessary downstream tests through improved diagnostic accuracy. These findings support its adoption in Finnish healthcare systems.
引用
- Brix MAK, Okkonen M, Mäkelä T, et al. Cost-effectiveness of photon counting detector CT for coronary artery disease diagnostics: A Finnish healthcare perspective. Eur J Radiol. 2025. PMID: 40540955. doi:10.1016/j.ejrad.2025.112245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。